1.6 Nutritional Support & Management of Dysphagia/Odynophagia

1.6 Nutritional Support & Management of Dysphagia/Odynophagia

Nutritional depletion and swallowing dysfunction represent severe, highly prevalent complications in radiation oncology. Patients undergoing radiotherapy to the head and neck, thoracic, upper gastrointestinal, or pelvic regions face significant metabolic and anatomical challenges. Radiation-induced inflammatory reactions—such as acute oral mucositis, pharyngeal constrictor irritation, xerostomia, radiation enteritis, and altered taste—directly compromise oral intake. Maintaining adequate nutritional status and managing swallowing impairment through early collaboration with a Registered Dietitian Nutritionist (RDN) and Speech-Language Pathologist (SLP) are critical to preserve immunocompetence, minimize toxic treatment breaks, prevent setup errors, and optimize clinical outcomes.

---

Cancer Cachexia & Malnutrition Pathophysiology

Cancer cachexia is a complex, multifactorial hypermetabolic syndrome characterized by an involuntary, progressive loss of skeletal muscle mass (with or without loss of adipose tissue) that cannot be fully reversed by conventional nutritional support. Unlike simple starvation, which primarily depletes adipose tissue while sparing lean body mass, cachexia drives preferential degradation of skeletal muscle.

                  [ TUMOR-DERIVED & HOST CYTOKINES ]
                      (TNF-α, IL-6, IL-1, IFN-γ)
                                  |
         +------------------------+------------------------+
         |                                                 |
  SYSTEMIC HYPERMETABOLISM                      SKELETAL MUSCLE CATABOLISM
  - Basal metabolic rate increased              - Ubiquitin-proteasome pathway
  - Persistent systemic inflammation             - Muscle protein breakdown > synthesis
         |                                                 |
         +------------------------+------------------------+
                                  |
                       [ CANCER CACHEXIA ]
                                  |
              Progressive Lean Body Mass Degradation
                                  |
             Unintentional Weight Loss (>5% in 30 Days)

Cytokine-Mediated Metabolic Reprogramming

The pathophysiology of cancer cachexia is mediated by tumor-derived factors and host pro-inflammatory cytokines, notably Tumor Necrosis Factor-alpha (TNF-$\alpha$) (historically called cachectin), Interleukin-6 (IL-6), Interleukin-1 (IL-1), and Interferon-gamma (IFN-$\gamma$). These cytokines alter central hypothalamic metabolic regulation, causing severe anorexia, and activate systemic catabolic pathways:

• Proteolysis & Muscle Degradation: Cytokines upregulate the ATP-dependent ubiquitin-proteasome pathway, driving rapid breakdown of structural muscle proteins (myosin and actin) while simultaneously inhibiting anabolic protein synthesis.
• Lipolysis & Fat Depletion: Enhanced activation of hormone-sensitive lipase leads to rapid breakdown of triacylglycerols in adipose tissue while suppressing lipogenesis.
• Hypermetabolism: Resting energy expenditure (REE) is significantly elevated due to uncoupled oxidative phosphorylation and altered carbohydrate/lipid metabolism.

---

Impact on Radiation Delivery, Setup Errors & Dosimetry

Unintentional weight loss is a critical clinical marker in radiation therapy. Clinical threshold criteria defining severe, high-risk malnutrition include:

• Unintentional weight loss >5% of baseline body weight within 30 days, OR
• Unintentional weight loss >10% of baseline body weight within 6 months (180 days).

Anatomical Alterations & Geometric Setup Errors

Significant loss of superficial subcutaneous fat and deep muscular tissue fundamentally alters external body contours. In head and neck radiation therapy, facial and cervical tissue shrinkage causes custom rigid thermoplastic immobilization masks to fit loosely.

+-------------------------------------------------------------------------+
|                DOSIMETRIC IMPACT OF WEIGHT LOSS IN RT                   |
+-------------------------------------------------------------------------+
|  1. IMMOBILIZATION BREAKDOWN                                            |
|     - Thermoplastic mask becomes loose due to facial/neck tissue loss.  |
|     - Patient head movement inside mask increases during fraction.      |
+-------------------------------------------------------------------------+
|  2. GEOMETRIC ALIGNMENT ERRORS                                          |
|     - Target volumes (GTV/CTV/PTV) shift relative to skin marks/lasers.  |
|     - Risk of missing tumor margins (under-dosing target volume).       |
+-------------------------------------------------------------------------+
|  3. CRITICAL ORGAN OVERDOSE RISK                                        |
|     - Loss of subcutaneous tissue thickness brings surface closer to OARs.|
|     - High-dose gradient regions shift into sensitive structures       |
|       (e.g., spinal cord, brainstem, parotid glands).                   |
+-------------------------------------------------------------------------+
|  4. MANDATORY CLINICAL ACTION                                           |
|     - Pause treatment when mask misfit or >5% weight loss is detected.  |
|     - Perform mandatory Adaptive CT Re-simulation and Re-planning.      |
+-------------------------------------------------------------------------+

When an immobilization device loses intimate contact with anatomical landmarks, intra-fraction patient movement increases, causing geometric setup errors. Radiation beams aligned to external lasers or surface contours can misregister with internal tumor targets. This leads to tumor geographic miss and shifts steep dose gradients onto critical organs-at-risk (OARs), such as exceeding the 45–50 Gy safety threshold on the spinal cord, leading to radiation-induced myelopathy. Radiation therapists must monitor daily mask fit and patient weight; significant changes mandate immediate notification of the radiation oncologist and dosimetrist for adaptive CT re-simulation and plan re-optimization.

---

Dysphagia & Odynophagia Pathophysiology

Swallowing dysfunction is a major adverse effect of radiation therapy encompassing head and neck, lower pharyngeal, or esophageal portals:

• Dysphagia: Difficulty or inability to swallow, resulting from mucosal inflammation, edema, pharyngeal constrictor muscle (superior, middle, inferior constrictors) spasm, late fibrosis of swallowing musculature, or tumor mass effect.
• Odynophagia: Painful swallowing, primarily driven by mucosal ulceration and denudation (radiation mucositis or esophagitis). Acute odynophagia typically manifests at cumulative radiation doses of ~20 Gy (weeks 2–3 of standard fractionation) and escalates through 40–50 Gy.

Diagnostic Swallow Evaluations & Silent Aspiration

When patients present with coughing during meals, wet/gurgly vocal quality, or recurrent unexplained fevers, formal swallowing evaluation by an SLP is mandatory. Swallowing therapy exercises (such as the Mendelsohn maneuver or effortful swallow) help preserve muscular tone.

Silent Aspiration Detection: A critical objective of MBSS/FEES is detecting silent aspiration—the entry of food or liquid below the true vocal folds into the trachea and lungs without triggering a coughing reflex. Silent aspiration occurs frequently in irradiated patients due to radiation-induced pharyngeal sensory loss and carries a high mortality risk from severe aspiration pneumonia.

---

Dietary Modifications & The IDDSI Framework

To prevent aspiration and maintain oral hydration, dietary textures and liquid viscosities are modified according to the International Dysphagia Diet Standardisation Initiative (IDDSI) framework, which standardizes terminology across 8 levels (Levels 0–7).

---

Nutritional & Caloric Augmentation

When oral intake is impaired by dysphagia or odynophagia, targeted nutritional augmentation is required to combat lean tissue catabolism:

• Caloric Target: 30 to 35 kcal/kg/day of actual or ideal body weight.
• Protein Target: 1.2 to 1.5 g/kg/day to compensate for cytokine-driven muscle breakdown and support mucosal repair.
• Fluid Requirements: 30 to 35 mL/kg/day to maintain hydration and renal clearance of chemotherapy and cellular breakdown products.
• High-Density Oral Nutritional Supplements (ONS): Concentrated commercial liquid formulas providing 1.5 to 2.0 kcal/mL (e.g., Ensure Plus, Boost VHC) consumed in small volume sips between meal attempts to maximize caloric density without overloading pharyngeal clearance.

---

Analgesic Pre-Medication Protocols

Severe odynophagia limits compliance with dietary intake. To enable adequate oral nutrition, topical and systemic analgesics must be strategically timed prior to meals:

                  [ PRE-MEAL ANALGESIC TIMING PROTOCOL ]
                                    |
           20 TO 30 MINUTES PRIOR TO SCHEDULED MEALS
                                    |
     +------------------------------+------------------------------+
     |                                                             |
  TOPICAL MUCOSAL ANESTHETICS                   SYSTEMIC SHORT-ACTING OPIOIDS
  - 2% Viscous Lidocaine (15 mL swish/spit)    - Oral Oxycodone (5-10 mg PO)
  - Compounded "Magic Mouthwash"                - Liquid Morphine (10-20 mg PO)
    (Lidocaine + Diphenhydramine + Antacid)     - Manages transmucosal pain

1. Topical Mucosal Anesthetics: Administer 2% Viscous Lidocaine (15 mL swish-and-spit) or compounded magic mouthwash (containing viscous lidocaine, liquid diphenhydramine, and aluminum/magnesium hydroxide antacid) 20 to 30 minutes prior to meals. This numbs mucosal nerve endings during eating.
2. Short-Acting Systemic Opioids: For severe submucosal pain, administer short-acting oral opioids (e.g., oral oxycodone 5–10 mg or liquid morphine 10–20 mg) 30 to 45 minutes before main meals.

---

Enteral & Parenteral Feeding Indications

When oral intake falls below 60% of total caloric requirements for more than 7 to 14 days, or when weight loss exceeds 10% of baseline, tube feeding intervention is indicated.

+-------------------------------------------------------------------------+
|                     ENTERAL VS. PARENTERAL SELECTION                    |
+-------------------------------------------------------------------------+
|  NASOGASTRIC (NG) TUBE                                                  |
|  - Route: Transnasal into stomach                                       |
|  - Duration: Short-term (<4 weeks)                                      |
|  - Considerations: Visible, uncomfortable, nasal erosion risk           |
+-------------------------------------------------------------------------+
|  PERCUTANEOUS ENDOSCOPIC GASTROSTOMY (PEG) TUBE                         |
|  - Route: Direct surgical stoma through abdominal wall into stomach    |
|  - Duration: Long-term (>4 weeks)                                       |
|  - Considerations: Hidden under clothing, stable, low aspiration risk   |
+-------------------------------------------------------------------------+
|  TOTAL PARENTERAL NUTRITION (TPN)                                       |
|  - Route: Central venous catheter (PICC / Port-a-Cath)                  |
|  - Duration: Non-functional GI tract (severe enteritis/obstruction)     |
|  - Considerations: High risk of central line sepsis & liver toxicity    |
+-------------------------------------------------------------------------+

Prophylactic vs. Reactive Tube Placement

Prophylactic PEG tube placement is strongly recommended prior to initiating concurrent chemoradiotherapy for locally advanced head and neck cancers (Stage III–IV). Prophylactic placement reduces emergency room visits, prevents severe dehydration, and avoids treatment interruptions compared to reactive placement during acute mucositis.